“…It is a novel multi-target TKI that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR a/b, c-Kit, and Ret. In so-doing, it effectively suppresses tumor angiogenesis and growth, with acceptable toxicity as seen in lu ng squamous cell carcinoma, advanced lung adenocarcinoma, small cell lung cancer, soft tissue sarcoma, medullary thyroid cancer, and metastatic renal clear cell cancer (Han et al, 2018;Sun et al, 2018;Shao et al, 2019;Yang et al, 2019;Zhou et al, 2019). Its major side effects include fatigue, high blood pressure, hand-foot skin reaction, gastrointestinal reactions, triglyceride elevation cholesterol elevation, and blood thyrotrophin elevation (Sun et al, 2016;Shao et al, 2019;Wang et al, 2020).…”